Glenmark Pharma reported a sharp 56.78% year-on-year decline in consolidated net profit to Rs 263.83 crore in Q2 FY27, reflecting significant pressure on its quarterly earnings.
During a conference, Ayumu Okada, President and CEO, OMRON HEALTHCARE Co., Ltd., and Junta Tsujinaga, President and CEO, Omron Corporation, discussed India's growing role as a global manufacturing and innovation hub, the opportunities for...
Lupin Q2 FY27 results reveal a 22% net profit decline despite revenue growth, highlighting rising expenses and margin pressures.
Hikma's branded drug growth is strengthening its 2026 outlook, with cardiovascular, diabetes and CNS medicines gaining momentum despite continued weakness in injectables revenue.
AstraZeneca’s 10 billion bid for Rhythm Pharmaceuticals highlights how obesity science is becoming a strategic priority beyond mainstream weight-loss treatments.
Sterile drug manufacturing faces tighter contamination controls as India proposes WHO-aligned microbial limits, placing cleanroom monitoring and pharmaceutical quality assurance under greater scrutiny.
Teva raises its 2026 outlook as branded medicines gain ground, with Austedo, Ajovy and Uzedy strengthening earnings despite generics pressure.
BioMerieux's latest results highlight how pharma quality control, mycoplasma testing and advanced microbiological solutions are becoming important drivers of growth in industrial diagnostics.
India’s pharmaceutical industry is moving into a new phase of growth, where the differentiator will be not just manufacturing scale, but the ability to demonstrate consistent quality, scientific rigour and regulatory readiness across markets.
Granules India delivers a robust second-quarter performance in FY27 as net profit climbs 39% to Rs 182 crore while revenue advances 20% to Rs 1,560 crore.
.jpg)
, CDSCO.jpg)
